Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized Amikacin for Gram-negative Bacillus Pneumonia in VA-ECMO Patients
NCT06602557Phase 2Recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Aug 2026
- Primary completion
- Aug 2028
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of amikacin liposome inhalation suspension in pneumonia (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Bacterial eradication rate at Day 5. Started Aug 2026; status: recruiting.
02
Drugs
amikacin liposome inhalation suspension
03
Conditions
pneumonia
Beyond the preview
Go deeper on NCT06602557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06602557.